部份中文左卡尼汀处方资料（仅供参考）
商品名：L-Cartin FF tablets
英文名：Levocarnitine
中文名：左卡尼汀片
生产商：大冢制药
药品简介
L-Cartin（Levocarnitine，左卡尼汀）是一种用途广泛的氨基酸类药物，加本品替补疗法用于长期的血液透析、左卡尼汀缺乏症、肌肉营养不良、心肌病、急性和慢性心肌梗塞形成、心绞痛、三环类抗抑郁药引起的心律失常、老年性痴呆症、早老性痴呆以及机能衰弱。 エルカルチンFF錠100mg/エルカルチンFF錠250mg
药效分类名称
左卡尼汀制剂
批准日期：2014年 12月
商標名
L-Cartin FF tablets 100mg
L-Cartin FF tablets 250mg
一般的名称
レボカルニチン〔Levocarnitine（JAN）〕
化学名
(R)-3-Hydroxy-4-trimethylammoniobutanoate
分子式
C7H15NO3
分子量
161.20
性状
它是一种白色结晶粉末。极易溶于水，微溶于乙醇(99.5)。它是吸湿的。水溶液的pH值（1→20）为6.5-8.5。
化学構造式
融点
约200°C（分解）
处理注意事项
打开铝枕后，请将其存放在远离潮湿的地方。
药效药理
作用机制
左旋肉碱的给药可纠正组织中的慢性肉碱缺乏症，并将组织中过量积累的有害丙酰基作为丙酰肉碱排出体外（尿）。它还保护线粒体功能免受有害丙酰基的影响，并激活其新陈代谢。
对线粒体呼吸能力的影响
使用大鼠肝线粒体，将左旋肉碱氯化物（l-型）与光学异构体 d-肉碱氯化物和dl-肉碱氯化物进行比较。结果，l型对线粒体呼吸活性没有抑制作用，而对丙酸对线粒体呼吸能力的抑制作用（体外）显示出显着的恢复作用。
适应症
肉碱缺乏症
用法与用量
成人，每天分3次口服1.5至3g左卡尼汀。剂量可根据患者情况调整。
儿童的常用剂量是每天每公斤体重25至100毫克左卡尼汀，分3次口服给药。剂量可根据患者情况调整。
包装
FF片剂
100mg：PTP：100片（10片×10）、500片（10片×50）
250mg：PTP：100片（10片×10）、500片（10片×50）
制造商和分销商
大冢制药株式会社 注：以上中文处方资料不够完整，使用者以原处方资料为准。
完整说明资料附件： https://www.info.pmda.go.jp/go/pack/3999033F1026_1_05/?view=frame&style=XML&lang=ja
--------------------------------------------------
L-Cartin FF tablets（Levocarnitine）エルカルチンFF錠
Otsuka Pharmaceutical Acquired Domestic Approval for Dosage Form with "Elcalcine FF Tablet" for Carnitine Deficiency Treatment
Improve convenience of medical site
On June 27, Otsuka Pharmaceutical Co., Ltd. announced that it acquired domestic approval for addition of a dosage form for "carcino-deficiency treatment drug" Elcalcine (R) FF tablet ".
This product uses levocarnitine(free body) which is the same active ingredient as "Elcalcine FF internal use liquid 10%" or "Elcalcine FF intravenous injection 1000 mg" released in 2013.
It eliminates the complexity of dose conversion and contributes to improving the convenience of the medical field.
Enable to provide appropriate continuous administration options
In 1990, Otsuka launched "Elcalcine Tablets" as an indication for improving levocarnitine deficiency in propionic acidemia and methylmalonic acidemia. Based on the eva luation that there is a need for additional indications from the Japan Society for Congenital Metabolic Syndrome and the Japanese Pediatrics Association, and that it is a publicly-known application at unconfirmed drugs/non-indication study consultation meeting with high medical necessity, in March 2011, carnitine Adaptation to deficiency, change of dosage and dose were made.
In February 2013, upon request from the Review Committee, we released internal liquid medications and injectable medicines as preparations that can be used for patients who can not drink tablets or can not be taken orally. However, since Elcalcine tablets were chloride, when changing the dosage form, it was necessary to prescribe dosage conversion.
About this acquisition approval In the press release
By being able to use 3 free form preparations of the same ingredients, we expect to offer appropriate continuous administration options to patients with carnitine deficiency and contribute to treatment.
